(COLL) Collegium Pharmaceutical, Inc. ANSOFF Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(COLL) Collegium Pharmaceutical, Inc. Complete Analysis Pack
Explore the Complete Growth Strategy Behind the Preview
This Collegium Pharmaceutical, Inc. Ansoff Matrix Analysis maps growth options across market penetration, market development, product development, and diversification to show strategic paths and priorities; the page includes a real preview/sample so you can judge style and depth before buying. Purchase the full version to receive the complete, ready-to-use company-specific analysis for research, strategy, or investment use.
Market Penetration
Xtampza ER formulary defense
Xtampza ER is Collegium Pharmaceutical, Inc.'s abuse-deterrent oxycodone for severe, persistent pain, and market penetration means protecting share in existing U.S. pain accounts. The key is steady payer access and prescriber retention, because formulary loss can quickly cut scripts and refill volume. In 2025, this is a defense game: keep the brand preferred, keep it covered, and stop erosion in established accounts.
Nucynta franchise retention
Collegium Pharmaceutical, Inc. keeps Nucynta Franchise Retention strong by pairing Nucynta ER and Nucynta IR, giving it 2 tapentadol options in one franchise. That helps defend share with chronic and acute pain prescribers already using tapentadol, so the brand stays embedded in the same treatment pathway. The 2-product setup also reduces switching risk and supports repeat prescribing.
Belbuca share growth
BELBUCA adds buprenorphine buccal film to Collegium Pharmaceutical, Inc.'s pain mix, so market penetration means deeper use among clinicians treating 24/7 chronic pain. It grows branded-opioid share inside the same U.S. patient pool by giving prescribers another option for ongoing pain management.
Symproic add-on prescribing
Symproic (naldemedine) extends Collegium Pharmaceutical, Inc.’s reach inside the same opioid-treated patient base as its pain brands, so prescribers can add it when opioid-induced constipation appears. That matters because OIC affects about 40% to 80% of chronic opioid users, which supports repeat prescribing and tighter portfolio stickiness.
- Same patient base
- Repeat add-on use
- Supports portfolio stickiness
U.S. specialty-prescriber focus
Collegium Pharmaceutical, Inc. is a U.S.-only specialty pharma company, so market penetration means going deeper with pain specialists and other opioid-prescribing clinicians, not entering new geographies. The clearest share-growth lever is heavier call coverage and tighter account focus in the same prescribing base.
That fits a depth-over-breadth play: more scripts per account, better retention, and stronger access in the core pain channel. In Ansoff terms, this is classic market penetration, where growth comes from existing products and existing U.S. prescribers.
- U.S. focus limits geographic expansion.
- Pain specialists drive the key share gains.
- Growth depends on account depth.
Collegium’s U.S. Pain Portfolio Drives Repeat Scripts and Share Defense
Collegium Pharmaceutical, Inc.'s market penetration is a U.S. share-defense play: keep Xtampza ER, Nucynta, BELBUCA, and Symproic inside the same pain-prescribing base. Growth comes from more scripts per account, strong payer access, and lower switching, not new geographies. OIC affects 40% to 80% of chronic opioid users, so add-on use supports repeat prescribing.
| Driver | Penetration effect |
|---|---|
| Xtampza ER | Protects U.S. share |
| Nucynta | Retains tapentadol users |
| BELBUCA | Deepens chronic-pain use |
| Symproic | Adds OIC follow-on scripts |
What is included in the product
Detailed Word Document
Provides a clear Ansoff Matrix framework for analyzing Collegium Pharmaceutical, Inc.’s growth strategy across existing and new products and markets
Editable Excel File
Provides a concise Collegium Pharmaceutical Ansoff Matrix to quickly clarify growth options and ease strategic planning.
Reference Sources
Cites primary regulatory filings, investor presentations, clinical studies, and financial reports to validate Ansoff Matrix growth paths for Collegium Pharmaceutical, Inc.
Market Development
Nucynta IR acute-pain segment
Nucynta IR is tapentadol immediate-release, sold in 50 mg, 75 mg, and 100 mg tablets, so it can serve short-term acute pain as well as chronic pain use. This is market development in Ansoff terms: the same product is pushed into a new patient segment, expanding Collegium Pharmaceutical, Inc. beyond its core long-term pain base. Acute pain is a large, high-turnover setting, so even modest share gains can add meaningful refill and new-start volume.
Xtampza ER post-acute settings
Xtampza ER is approved for severe, persistent pain needing daily, continuous, long-term opioid therapy, so moving it into post-acute and continuing-care settings extends the same brand beyond hospital use. That is market development: Collegium Pharmaceutical, Inc. is widening where the product is prescribed, especially after discharge, in rehab, and in long-term care.
Belbuca chronic-pain clinics
Belbuca is positioned for patients who need around-the-clock opioid analgesia, so moving deeper into chronic-pain clinics and specialist channels widens prescribing without changing the product. This is market development in Ansoff terms: same brand, more sites of care, more eligible patients. Collegium Pharmaceutical, Inc. can grow Belbuca by reaching pain physicians and clinic networks that already treat persistent pain.
Symproic opioid-induced constipation base
Symproic treats opioid-induced constipation in adults, so it extends Collegium Pharmaceutical, Inc. beyond pain control into supportive care. With constipation affecting roughly 40% to 80% of patients on opioids, the base expands as more treated patients keep long-term opioid use.
- Targets adults with opioid-induced constipation
- Broadens use across opioid-treated patients
- Adds supportive care beyond pain relief
That makes Symproic a market development play: deeper penetration in the same patient pool without changing the core product need. In 2025, its role stayed tied to chronic opioid users, where persistence and repeat use matter most.
Broader U.S. payer access
Broader U.S. payer access is a clean market-development move for Collegium Pharmaceutical, Inc.: the products stay in the same U.S. market, but more commercial and government plans can widen coverage. Because Collegium’s 2024 net product sales topped $680 million, even small gains in formulary access can lift prescription volume fast.
With most U.S. drug spend routed through payer and pharmacy channels, access wins matter more than geography. Extending coverage for existing brands can add patients without a new launch.
- Same geography, wider customer base
- More formulary wins can boost scripts
- Access gaps still limit brand growth
Collegium Expands Existing Brands Into New Patients
Collegium Pharmaceutical, Inc. is using market development by pushing existing brands into new patient and care settings, not changing the drugs. In 2025, Symproic stayed tied to chronic opioid users, and broader payer access could lift scripts across the same U.S. market.
| Driver | 2025/2024 data |
|---|---|
| Net product sales | >$680M in 2024 |
| Growth lever | Formulary access |
| Use case | Same brands, new patients |
What You See Is What You Get
Collegium Pharmaceutical, Inc. Reference Sources
This is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality, applied to Collegium Pharmaceutical’s growth options across market penetration, product development, market development, and diversification.
Product Development
Xtampza ER abuse-deterrent design
Xtampza ER is Collegium Pharmaceutical, Inc.'s abuse-deterrent, extended-release oxycodone, so it fits product development: the Company Name is improving the drug design, not entering a new pain segment. It gives prescribers a branded alternative to conventional oxycodone ER, and Company Name's pain portfolio has continued to drive more than $600 million in annual net sales in recent recent reporting.
Nucynta ER extended-release tapentadol
Nucynta ER (extended-release tapentadol) adds a long-acting opioid option for chronic pain, so Collegium Pharmaceutical, Inc. broadens its pain portfolio without leaving its core market. The ER form gives the company a distinct dosage type for patients who need around-the-clock pain control.
In Ansoff Matrix terms, this is product development: a new format built for the same pain segment, not a move into a new market. It strengthens the lineup around tapentadol while keeping the commercial focus on chronic pain treatment.
Nucynta IR immediate-release tapentadol
Nucynta IR is the immediate-release tapentadol form, adding a second dosage form to Collegium Pharmaceutical, Inc.'s franchise. It targets acute pain inside the same therapeutic area, so this is product development in the Ansoff Matrix, not a new market move. The two-form strategy helps the Company cover both chronic and acute pain needs with one molecule.
Belbuca buprenorphine buccal film
Belbuca, a buprenorphine buccal film, expands Collegium Pharmaceutical, Inc.'s pain portfolio with a branded option for chronic pain patients needing opioid analgesia. It is a clear product-line expansion because it adds a different dosage form and route of delivery to the Company Name's existing offerings.
- Branded buprenorphine buccal film
- Targets chronic pain opioid users
- Expands the pain product line
Symproic naldemedine 0.2 mg
Symproic, naldemedine 0.2 mg, adds a once-daily opioid-induced constipation option to Collegium Pharmaceutical, Inc.’s portfolio. It fits the same opioid care ecosystem as Collegium Pharmaceutical, Inc.’s pain brands, so it supports product development by deepening the stack around one patient group. OIC affects about 40% to 80% of chronic opioid users, so the cross-sell fit is clear.
- 0.2 mg naldemedine dose
- Targets opioid-induced constipation
- Supports the same pain-care niche
Collegium Expands Its Pain Franchise Through Product Development
Collegium Pharmaceutical, Inc. is using product development by extending its pain franchise with new dosage forms and delivery routes, not by entering a new market. Xtampza ER, Nucynta ER, Nucynta IR, Belbuca, and Symproic all deepen the same opioid-care niche, and the pain portfolio has generated more than $600 million in annual net sales.
| Brand | Role | Ansoff fit |
|---|---|---|
| Xtampza ER | Abuse-deterrent oxycodone ER | Product development |
| Nucynta ER/IR | Tapentadol line extension | Product development |
| Belbuca | Buprenorphine buccal film | Product development |
| Symproic | OIC therapy | Adjacent line extension |
Diversification
Ironshore acquisition, 2023
Collegium Pharmaceutical, Inc. bought Ironshore Therapeutics in 2023 for about $525 million, adding a non-pain specialty asset to its portfolio. That move was pure diversification in the Ansoff Matrix: it opened a new product family and a new market beyond its pain franchise. The deal also widened Collegium’s revenue base, with Ironshore’s specialty assets giving it more than one growth engine.
Jornay PM methylphenidate
Jornay PM, methylphenidate HCl for ADHD, is a different molecule from Collegium Pharmaceutical, Inc. pain brands, so it broadens the product mix into a new therapeutic category.
In Ansoff terms, this is diversification because the company is serving a new market with a non-core asset, not just extending its pain franchise.
That lowers dependence on opioid and non-opioid pain revenue and gives Collegium Pharmaceutical, Inc. a second growth path if ADHD adoption keeps building.
ADHD market entry
Jornay PM moved Collegium Pharmaceutical, Inc. into ADHD, a market outside its legacy pain franchise, so this is diversification, not market penetration. U.S. ADHD affects about 7 million children ages 3-17, giving Collegium a new patient pool and use case versus its opioid and non-opioid pain base. That shift also adds a second growth engine beyond pain.
Evening-dosed CNS therapy
Jornay PM adds evening-dosed CNS coverage to Collegium Pharmaceutical, Inc., using a delayed-release, extended-release stimulant that works differently from its opioid brands. That broadens the portfolio beyond pain and supports diversification into ADHD care, a market with millions of U.S. patients treated each year.
- Different dose timing and mechanism
- Expands beyond opioid revenue
- Adds non-pain specialty-therapy exposure
Non-pain revenue mix
Jornay PM broadens Collegium Pharmaceutical, Inc. beyond pain, so the company is no longer tied to a single therapy lane. That adds CNS specialty prescribing to a base that still includes pain medicines, which is the main diversification gain.
This matters because more than 1 revenue stream can soften mix risk if pain demand slows. The move also gives Collegium Pharmaceutical, Inc. a second specialist sales channel and deeper prescriber reach.
- Less pain-only exposure
- More CNS revenue mix
- Broader prescriber base
Collegium Expands Beyond Pain With $525M ADHD Deal
Collegium Pharmaceutical, Inc. used diversification when it bought Ironshore Therapeutics in 2023 for about $525 million and added Jornay PM, a non-pain ADHD asset. That moved the company into a new therapy area beyond its core pain franchise. With about 7 million U.S. children ages 3-17 affected by ADHD, the deal gives Collegium Pharmaceutical, Inc. a second growth path.
| Item | Data |
|---|---|
| Deal | Ironshore Therapeutics, 2023 |
| Price | About $525 million |
| New market | ADHD |
| U.S. patient pool | About 7 million children |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.